Parkside Financial Bank & Trust Has $1.37 Million Position in Pfizer Inc. (NYSE:PFE)

Parkside Financial Bank & Trust boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 1.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 38,234 shares of the biopharmaceutical company’s stock after buying an additional 483 shares during the period. Parkside Financial Bank & Trust’s holdings in Pfizer were worth $1,374,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PFE. 1 North Wealth Services LLC bought a new position in Pfizer during the third quarter valued at about $29,000. Bourgeon Capital Management LLC bought a new position in Pfizer during the third quarter valued at about $32,000. Evolution Wealth Advisors LLC bought a new position in Pfizer during the second quarter valued at about $34,000. IMA Wealth Inc. grew its position in Pfizer by 144.5% during the second quarter. IMA Wealth Inc. now owns 807 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 477 shares during the period. Finally, B & T Capital Management DBA Alpha Capital Management bought a new position in Pfizer during the third quarter valued at about $36,000. Hedge funds and other institutional investors own 71.52% of the company’s stock.

In other news, Director Scott Gottlieb purchased 3,000 shares of the stock in a transaction dated Friday, August 23rd. The shares were purchased at an average cost of $34.72 per share, with a total value of $104,160.00. Following the completion of the acquisition, the director now owns 3,000 shares in the company, valued at approximately $104,160. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Pfizer Inc purchased 50,000 shares of the stock in a transaction dated Tuesday, September 17th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. Corporate insiders own 0.09% of the company’s stock.

PFE has been the subject of several research reports. Morgan Stanley reduced their price target on shares of Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a research report on Tuesday, August 27th. DZ Bank upgraded shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a research report on Wednesday, August 28th. Credit Suisse Group restated a “hold” rating and set a $41.30 price target on shares of Pfizer in a research report on Wednesday. JPMorgan Chase & Co. restated a “neutral” rating on shares of Pfizer in a research report on Tuesday, October 29th. Finally, UBS Group restated a “neutral” rating and set a $43.00 price target on shares of Pfizer in a research report on Monday, August 5th. Nine research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $44.02.

NYSE:PFE traded up $0.14 on Friday, reaching $37.05. 24,924,227 shares of the company’s stock were exchanged, compared to its average volume of 23,366,957. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.47 and a quick ratio of 1.21. The firm has a market cap of $207.30 billion, a price-to-earnings ratio of 12.35, a P/E/G ratio of 2.11 and a beta of 0.67. Pfizer Inc. has a 52 week low of $33.97 and a 52 week high of $46.47. The stock has a fifty day simple moving average of $36.62 and a 200-day simple moving average of $39.26.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.13. The firm had revenue of $12.68 billion during the quarter, compared to analyst estimates of $12.37 billion. Pfizer had a net margin of 30.57% and a return on equity of 28.61%. The company’s quarterly revenue was down 4.6% on a year-over-year basis. During the same quarter last year, the business earned $0.78 earnings per share. As a group, sell-side analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be issued a $0.36 dividend. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.89%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s payout ratio is 48.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: What are high-yield dividend stocks?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.